-
Pope hits out at jails in closed-off Equatorial Guinea
-
Atletico beaten again in Elche thriller
-
England rugby great Moody offered 'hope' in battle with motor neurone disease
-
PSG roll over Nantes to move closer to Ligue 1 title
-
Ecuador doctors protest crisis as patients bring own meds to surgery
-
Top Peru ministers quit in protest over stalled US fighter jet deal
-
De La Hoya and Ali's grandson slam proposed federal boxing reform
-
Archer, Burger turn up the heat as Rajasthan beat Lucknow in IPL
-
Trump alleges Democratic-backed Virginia referendum was 'rigged'
-
Archer, Burger help Rajasthan beat Lucknow in IPL
-
Migrants deported from US stranded, 'scared' in DR Congo
-
Raiders expected to make Mendoza first pick in NFL Draft
-
Chelsea sack Rosenior after worst run since 1912
-
Veteran Fijian Botia extends La Rochelle contract to 2027
-
Colombia's ambitious energy transition gets reality check
-
Liam Rosenior sacked as Chelsea manager
-
'Seriously fractured'? Scepticism over Trump's Iran leadership split claim
-
US doesn't dictate terms of trade talks: Carney
-
Mideast war weighs on parent of Durex condoms
-
Greek parliament lifts immunity of MPs probed in EU farm scandal
-
Just a little late: Frankfurt celebrates new airport terminal
-
Germany forward Gnabry confirms he will miss World Cup
-
Liam Rosenior sacked as Chelsea manager: club
-
Shifting goals blur picture of US blockade on Iran
-
US Treasury chief defends pivot to extend Russia oil sanctions relief
-
French teenager Seixas becomes youngest Fleche Wallonne winner
-
New drugs raise hopes of pancreatic cancer breakthrough
-
South Africa coal delay could cause 32,000 deaths, report says
-
French teenager Seixas becomes youngest winner of La Fleche Wallonne
-
Hezbollah supporters defiant after sons killed fighting Israel
-
EU unblocks 90-bn-euro Ukraine loan after Hungary row
-
Russia says will halt flow of Kazakh oil to Germany
-
Merz says climate policy must not 'endanger' German industry
-
Ziggy Stardust lives on at David Bowie London immersive
-
Thousands of London commuters walk to work in underground strike
-
Boeing reports narrowing loss, points to progress on turnaround
-
Oil up, stocks mixed on uncertain prospects for US-Iran ceasefire
-
Germany halves 2026 growth forecast on Iran war fallout
-
Chinese EVs look to sideline foreign brands at Beijing auto show
-
Russia to block flow of Kazakh oil to German refinery, Berlin says
-
Vietnam, South Korea sign deals on tech, nuclear power
-
EU nears approval of Ukraine loan after Hungary pipeline row
-
Duterte jurisdiction appeal quashed at ICC
-
Three ships targeted in Hormuz, Iran seizes two: monitors, Guards
-
Iran says seized two ships seeking to cross Strait of Hormuz
-
Iran murals project defiance in war with US
-
Oil prices rise despite US-Iran ceasefire extension
-
Ships attacked in Gulf as Trump extends Iran ceasefire
-
Germany set to slash growth forecast due to Mideast war
-
Pakistan's capital holds its breath with US-Iran talks in limbo
'Geneva patient' the latest in long-term remission from HIV
A man dubbed the "Geneva patient" is the latest person with HIV to be declared in long-term remission -- however he did not receive a transplant with a virus-blocking gene mutation like previous cases, researchers said Thursday.
Five people have previously been considered "cured" of HIV: the Berlin, London, Duesseldorf, New York and City of Hope, California patients.
All had bone marrow transplants to treat serious cases of cancer, receiving stem cells from a donor with a mutation of the CCR5 gene. This mutation is known to block HIV from entering the body's cells.
In 2018, the Geneva patient similarly received a stem cell transplant to treat a particularly aggressive form of leukaemia.
But this time the transplant came from a donor who did not carry the CCR5 mutation, French and Swiss researchers told a press conference in the Australian city of Brisbane as part of an AIDS conference that begins at the weekend.
This means that the virus is still able to enter the patient's cells.
However, 20 months after the man stopped taking antiretroviral treatment -- which reduces the amount of HIV in the blood -- doctors at Geneva University Hospitals have not found a trace of the virus in his system, the researchers said.
While they cannot rule out that the man's HIV will return, the researchers said they consider him to be in long-term remission.
"What is happening to me is magnificent, magical," the Geneva patient said in a statement.
The patient, a white man who chose not to be named, was diagnosed with HIV in 1990.
He had been on antiretrovirals until November 2021, when his doctors advised him to stop taking the treatment after the bone marrow transplant.
- 'Promising' -
Two previous cases, known as the Boston patients, had also received normal or "wild type" stem cells during their transplants. But in both cases, HIV returned a few months after they stopped taking antiretrovirals.
Asier Saez-Cirion, a scientist at France's Pasteur Institute who presented the Geneva patient case in Brisbane, told AFP that if there was still no sign of the virus after 12 months "the probability that it will be undetectable in the future increases significantly".
There were a couple of possible explanations for why the Geneva patient remains HIV free, Saez-Cirion said.
"In this specific case, perhaps the transplant eliminated all the infected cells without the need for the famous mutation," he said.
"Or maybe his immunosuppressive treatment, which was required after the transplant, played a role."
Sharon Lewin, the president of the International AIDS Society holding the HIV science conference in Brisbane, said the case was "promising".
"But we learned from the Boston patients that even a single" particle of the virus can lead to HIV rebounding, she cautioned.
"This particular individual will need to be watched closely over the next months and years."
While these cases of long-term remission raise hopes that one day HIV can truly be cured, the brutal and risky bone marrow transplant procedure is not an option for the millions of people living with the virus around the world.
It is instead a last-ditch attempt to treat life-threatening cancer in people who also have HIV.
However, there are hopes that the remission cases could point towards new avenues of research, such as the potential role played by immunosuppressive treatments.
Saez-Cirion said the case had also encouraged the researchers to continue studying innate immune cells, which act as the first line of defence against various pathogens, and could help control the virus.
For his part, the Geneva patient said he was now "looking to the future".
T.Khatib--SF-PST